<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="article-id" content="science-medical-isotope-20251114">
    <meta name="article-category" content="Science">
    <meta name="article-author" content="Mirage News">
    <meta name="article-date" content="Nov 14, 2025">
    <meta name="article-readtime" content="2">
    <meta name="article-source" content="https://www.miragenews.com/ansto-delivers-new-medical-radioisotope-1121359/">
    <meta name="article-trending" content="true">
    <meta name="article-video" content="false">
    <meta name="article-video-url" content="">
    <meta name="description" content="Australian health researchers at ANSTO have achieved a significant milestone, producing the nation&#8217;s first batch of terbium-161.">
    <meta name="og:title" content="ANSTO Achieves Breakthrough with First Australian Production of Cancer-Fighting Isotope">
    <meta name="og:description" content="Australian health researchers at ANSTO have achieved a significant milestone, producing the nation&#8217;s first batch of terbium-161.">
    <meta name="og:image" content="https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?q=80&w=2070&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D">
    <meta name="og:url" content="https://www.miragenews.com/ansto-delivers-new-medical-radioisotope-1121359/">
    <title>ANSTO Achieves Breakthrough with First Australian Production of Cancer-Fighting Isotope - NewsHub</title>
    <link rel="stylesheet" href="../css/article-magazine.css">
    <link rel="stylesheet" href="../css/layout-grid.css">
    <style>
        body {
            margin: 0;
            padding: 20px;
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            line-height: 1.6;
            background-color: #f5f5f5;
        }
        .article-container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            padding: 40px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
        }
        .article-header {
            margin-bottom: 30px;
        }
        .article-meta {
            color: #666;
            font-size: 0.9em;
            margin-bottom: 20px;
        }
        .article-meta span {
            margin-right: 15px;
        }
        .back-link {
            display: inline-block;
            margin-bottom: 20px;
            color: #0066cc;
            text-decoration: none;
        }
        .back-link:hover {
            text-decoration: underline;
        }
    </style>
</head>
<body>
    <div class="article-container">
        <a href="../index.html" class="back-link">‚Üê Back to Home</a>
        <article class="article-header">
            <h1>ANSTO Achieves Breakthrough with First Australian Production of Cancer-Fighting Isotope</h1>
            <div class="article-meta">
                <span><strong>Category:</strong> Science</span>
                <span><strong>By:</strong> Mirage News</span>
                <span><strong>Published:</strong> Nov 14, 2025</span>
                <span><strong>Read time:</strong> 2 min</span>
                <span><strong>üî• Trending</strong></span>
            </div>
            <img src="https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?q=80&w=2070&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D" alt="ANSTO Achieves Breakthrough with First Australian Production of Cancer-Fighting Isotope" style="width: 100%; height: auto; margin-bottom: 20px;">
        </article>
        <div class="article-content">
            <div class="magazine-article">
                <div class="magazine-header-badge">SCIENCE</div>
                <div class="magazine-article-header">
                    <h1>ANSTO Achieves Breakthrough with First Australian Production of Cancer-Fighting Isotope</h1>
                    <p class="magazine-subtitle">Researchers have successfully produced and tested terbium-161, a promising medical radioisotope for personalised cancer treatment, marking a significant advancement for nuclear medicine in Australia.</p>
                    <p class="magazine-byline">BY <strong>Mirage News</strong></p>
                </div>
                <div class="magazine-content-wrapper">
                    <div class="magazine-main-content">
                        <p class="magazine-lead-text">Australian health researchers at ANSTO have achieved a significant milestone, producing the nation‚Äôs first batch of terbium-161. This emerging medical radioisotope holds immense promise for developing more effective and personalised cancer treatments. The entire production pipeline, from creation in the OPAL multi-purpose reactor to successful preclinical imaging, was handled domestically.</p>
                        <p>The breakthrough is a testament to the collaborative power of diverse scientific teams at The Australian Nuclear Science and Technology Organisation (ANSTO). A complex process was developed to isolate, purify, and then attach the terbium-161 to a specialised drug that targets prostate cancer cells. This allows for highly targeted internal radiotherapy, a key strategy in modern oncology.</p>


                        <!-- First Inline Image -->
                        <div class="magazine-image-block">
                            <div class="magazine-image-container magazine-image-gradient-purple">
                                <img src="https://images.unsplash.com/photo-1581093450021-4a7360aa9a2f?q=80&w=2070&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D" alt="A scientist in a lab coat and gloves handling scientific equipment." style="max-width: 100%; height: auto; display: block;">
                                <div class="magazine-image-text">Sovereign Capability</div>
                            </div>
                            <div class="magazine-caption">The entire production pipeline for terbium-161 was developed and executed within Australia.</div>
                        </div>


                        <p><strong>A Complex Pipeline</strong> The production journey began inside the OPAL reactor, where the raw material was irradiated. Specialised automation technologies, designed and built by ANSTO, were crucial for safely processing the highly radioactive targets. Following retrieval, the terbium-161 had to be chemically separated from bulk materials before being converted into a form suitable for medical use.</p>


                        <p>Preclinical trials using a prostate cancer laboratory model confirmed the success of the process. High-resolution scans showed that the terbium-161-labelled drug was successfully absorbed by the tumour. The scans also demonstrated that the substance cleared from the body through the kidneys and bladder as intended, a critical factor for patient safety.</p>


                        <!-- Pull Quote -->
                        <div class="magazine-pullquote">&quot;It is a significant scientific achievement, demonstrating the expertise of ANSTO researchers to produce, purify and deliver a radioisotope for advanced imaging and potential use in treating cancer.&quot; &mdash; Dr John Bennett, ANSTO</div>


                        <p>The implications of this achievement are substantial for the future of Australian healthcare. Establishing a local supply of terbium-161 reduces reliance on international sources and accelerates research and development of new cancer treatments. The properties of terbium-161 are particularly attractive for treating cancers with high precision.</p>


                        <!-- Second Inline Image -->
                        <div class="magazine-image-block">
                            <div class="magazine-image-container magazine-image-gradient-indigo">
                                <img src="https://images.unsplash.com/photo-1628334465383-a265a6e1295e?q=80&w=1974&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D" alt="Detailed 3D rendering of cancer cells." style="max-width: 100%; height: auto; display: block;">
                                <div class="magazine-image-text">Targeted Therapy</div>
                            </div>
                            <div class="magazine-caption">The isotope is combined with a drug that specifically targets proteins found on prostate cancer cells.</div>
                        </div>


                        <p>Looking ahead, the ANSTO teams are preparing to expand their research program. This will involve comparing terbium-161 treatments with other therapeutic methods and evaluating new radiopharmaceuticals. The ultimate goal is to refine and develop improved strategies for patient treatment, leveraging this powerful new tool in the fight against cancer.</p>


                        <p>This project not only highlights Australia&#8217;s advanced nuclear capabilities but also positions the country as a key contributor to the global development of next-generation radiopharmaceuticals. The successful domestic production of terbium-161 is a critical step towards more accessible and effective cancer therapies for Australians.</p>
                    </div>


                    <!-- Sidebar -->
                    <div class="magazine-sidebar">
                        <!-- Sidebar Image -->
                        <div class="magazine-sidebar-image magazine-image-gradient-purple">
                            <img src="https://plus.unsplash.com/premium_photo-1676649839393-5d4c86a6d2f9?q=80&w=1974&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D" alt="The OPAL multi-purpose reactor facility." style="max-width: 100%; height: auto; display: block;">
                            <div class="magazine-sidebar-image-text">OPAL Reactor</div>
                        </div>
                        <div class="magazine-caption">The isotope was produced in Australia's only nuclear reactor, OPAL.</div>


                        <!-- By The Numbers Section -->
                        <div class="magazine-sidebar-box">
                            <h3>By The Numbers</h3>
                            <div class="magazine-stat-item">
                                <div class="magazine-stat-number">1st</div>
                                <div class="magazine-stat-label">Time Terbium-161 has been produced in Australia</div>
                            </div>
                            <div class="magazine-stat-item">
                                <div class="magazine-stat-number">161</div>
                                <div class="magazine-stat-label">The mass number of the promising Terbium isotope</div>
                            </div>
                            <div class="magazine-stat-item">
                                <div class="magazine-stat-number">1</div>
                                <div class="magazine-stat-label">Multi-purpose reactor (OPAL) used for production</div>
                            </div>
                            <div class="magazine-stat-item">
                                <div class="magazine-stat-number">2+</div>
                                <div class="magazine-stat-label">Key stages: Production, Purification &amp; Testing</div>
                            </div>
                        </div>


                        <!-- Key Context Section -->
                        <div class="magazine-sidebar-box">
                            <h3>The Role of Radioisotopes</h3>
                            <p>Medical radioisotopes are radioactive atoms that have a short half-life. When attached to specific molecules, they can be used to either diagnose or treat diseases.</p>
                            <p>In this case, Terbium-161 acts as a therapeutic agent. It is combined with a drug that seeks out a protein (PSMA) on the surface of prostate cancer cells, delivering a targeted dose of radiation directly to the tumour while minimising damage to surrounding healthy tissue.</p>
                        </div>
                    </div>
                </div>


                <!-- Bottom Full-Width Section -->
                <div class="magazine-bottom-section">
                    <div class="magazine-full-width-image magazine-image-gradient-indigo">
                        <img src="https://images.unsplash.com/photo-1532187643623-dbf267c4889c?q=80&w=1934&auto=format&fit=crop&ixlib=rb-4.0.3&ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D" alt="Abstract medical background showing molecular structures" style="max-width: 100%; height: auto; display: block;">
                        <div class="magazine-image-text" style="font-size: 32px;">The Future of Nuclear Medicine</div>
                    </div>
                    <div class="magazine-caption">ANSTO's research paves the way for new clinical trials and treatment strategies in Australia.</div>
                </div>
            </div>
        </div>
        <div style="margin-top: 40px; padding-top: 20px; border-top: 1px solid #ddd;">
            <a href="https://www.miragenews.com/ansto-delivers-new-medical-radioisotope-1121359/" target="_blank" rel="noopener noreferrer">Read original source ‚Üí</a>
        </div>
    </div>
</body>
</html>